These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 9794841)

  • 21. Daclizumab (humanized anti-IL2Ralpha mAb) prophylaxis for prevention of acute rejection in renal transplant recipients with delayed graft function.
    Bumgardner GL; Ramos E; Lin A; Vincenti F;
    Transplantation; 2001 Aug; 72(4):642-7. PubMed ID: 11544424
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Basiliximab versus daclizumab combined with triple immunosuppression in deceased donor renal transplantation: a prospective, randomized study.
    Kandus A; Arnol M; Omahen K; Oblak M; Vidan-Jeras B; Kmetec A; Bren AF
    Transplantation; 2010 Apr; 89(8):1022-7. PubMed ID: 20075788
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Induction immunotherapy with IL-2Ra monoclonal antibody in kidney transplantation.
    Ahsan N
    Minerva Urol Nefrol; 2003 Mar; 55(1):67-79. PubMed ID: 12773968
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Limited benefits of induction with monoclonal antibody to interleukin-2 receptor in combination with tacrolimus, mycophenolate mofetil, and steroids in simultaneous kidney-pancreas transplantation.
    Lo A; Stratta RJ; Alloway RR; Egidi MF; Shokouh-Amiri MH; Grewal HP; Gaber AO
    Transplant Proc; 2001; 33(1-2):1701-3. PubMed ID: 11267477
    [No Abstract]   [Full Text] [Related]  

  • 25. Induction therapy with daclizumab as part of the immunosuppressive regimen in human small bowel and multiorgan transplants.
    Carreño MR; Kato T; Weppler D; Mathew JM; Fuller L; Gomez C; Salman F; Garcia-Morales R; Ciancio G; Burke GW; Esquenazi V; Miller J; Tzakis AG
    Transplant Proc; 2001; 33(1-2):1015-7. PubMed ID: 11267170
    [No Abstract]   [Full Text] [Related]  

  • 26. Monoclonal antibody approved for renal transplants.
    Am J Health Syst Pharm; 1998 Feb; 55(3):207-8. PubMed ID: 9492247
    [No Abstract]   [Full Text] [Related]  

  • 27. [Therapeutic strategy for acute rejection in organ transplantation--optimal use of monoclonal antibody].
    Hanafusa T; Takahara S
    Nihon Rinsho; 2002 Mar; 60(3):598-602. PubMed ID: 11904979
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A review of interleukin-2 receptor antagonists in solid organ transplantation.
    Berard JL; Velez RL; Freeman RB; Tsunoda SM
    Pharmacotherapy; 1999 Oct; 19(10):1127-37. PubMed ID: 10512062
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Anti-interleukin 2-receptor antibodies: a comparative study with polyclonal antibodies in kidney transplantation: preliminary results.
    Martins L; Henriques AC; Dias L; Sarmento AM; Pereira MC; Guimarães S
    Transplant Proc; 2000 Dec; 32(8):2623-5. PubMed ID: 11134730
    [No Abstract]   [Full Text] [Related]  

  • 30. Comparison of daclizumab, an interleukin 2 receptor antibody, to anti-thymocyte globulin-Fresenius induction therapy in kidney transplantation.
    Abou-Jaoude MM; Ghantous I; Almawi WY
    Mol Immunol; 2003 Jul; 39(17-18):1083-8. PubMed ID: 12835081
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Results of 3-year phase III clinical trials with daclizumab prophylaxis for prevention of acute rejection after renal transplantation.
    Bumgardner GL; Hardie I; Johnson RW; Lin A; Nashan B; Pescovitz MD; Ramos E; Vincenti F;
    Transplantation; 2001 Sep; 72(5):839-45. PubMed ID: 11571447
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Daclizumab: a potential asthma therapy?
    Antoniu SA
    Recent Pat Inflamm Allergy Drug Discov; 2010 Nov; 4(3):214-21. PubMed ID: 20804450
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Randomized trial of three different immunosuppressive regimens to prevent chronic renal allograft rejection.
    Burke GW; Ciancio C; Blomberg BB; Rosen A; Suzart K; Roth D; Kupin W; Esquenazi V; Miller J
    Transplant Proc; 2002 Aug; 34(5):1610-1. PubMed ID: 12176505
    [No Abstract]   [Full Text] [Related]  

  • 34. The use of anti-interleukin-2 receptor antibodies in pediatric liver transplantation.
    Kelly DA
    Pediatr Transplant; 2001 Dec; 5(6):386-9. PubMed ID: 11737761
    [No Abstract]   [Full Text] [Related]  

  • 35. IL-2 receptor blockers in liver transplantation: initial experience with daclizumab in Chile.
    Innocenti F; Humeres R; Zamboni M; Sanhueza E; Zapata R; Hepp J; Rius M
    Transplant Proc; 2003 Nov; 35(7):2520-1. PubMed ID: 14612001
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of daclizumab (zenapax) on prevention of acute rejection of renal transplantation.
    Poorrezagholi F; Einollahi B; Firoozan A; Nafar M; Yadegari H; Moghaddam SM; Simforoosh N; Basiri A; Farhangi S
    Transplant Proc; 2003 Nov; 35(7):2735-6. PubMed ID: 14612098
    [No Abstract]   [Full Text] [Related]  

  • 37. Daclizumab: novel biologic immunoprophylaxis for prevention of acute rejection in renal transplantation.
    Vincenti F
    Transplant Proc; 1999 Sep; 31(6):2206-7. PubMed ID: 10500546
    [No Abstract]   [Full Text] [Related]  

  • 38. Daclizumab to prevent acute rejection in renal transplantation.
    Abramowicz D
    N Engl J Med; 1998 Jun; 338(23):1700-1. PubMed ID: 9616069
    [No Abstract]   [Full Text] [Related]  

  • 39. Interleukin-2 receptor blockade in cardiac transplantation: influence of HLA-DR locus incompatibility on treatment efficacy.
    Lietz K; John R; Beniaminovitz A; Burke EM; Suciu-Foca N; Mancini DM; Edwards NM; Itescu S
    Transplantation; 2003 Mar; 75(6):781-7. PubMed ID: 12660501
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Interleukin-2R antagonists in the prevention of acute rejection in living donor transplantation.
    Ivanovski N; Popov Z; Kolevski P; Cakalaroski K; Spasovski G; Sikole A; Paneva-Masin J
    Transplant Proc; 2001; 33(7-8):3203-4. PubMed ID: 11750374
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.